CET

Implantica presents the third quarter 2023 on November 22 at 15:00 CET

Retrieved on: 
Friday, November 17, 2023
Webcast, CET

VADUZ, Liechtenstein, Nov. 17, 2023 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2023 at 15:00 CET on November 22.

Key Points: 
  • VADUZ, Liechtenstein, Nov. 17, 2023 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2023 at 15:00 CET on November 22.
  • The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.
  • The presentation will be in English via an audiocast with teleconference:
    If you wish to participate via webcast, please use the following link:

RaySearch Laboratories: Interim report January 1 - September 30, 2023

Retrieved on: 
Friday, November 17, 2023
Paul Scherrer Institute, CFO, Mass, Cyberknife, CET, University Medical Center Groningen, RaySearch Laboratories, Lausanne University Hospital, University, Partnership, CHUV, Pharmaceutical industry, Nursing, Flour

RaySearch and MedAustron expand their partnership through a new strategic research agreement.

Key Points: 
  • RaySearch and MedAustron expand their partnership through a new strategic research agreement.
  • RaySearch's business partner IBA has placed an order for RayStation and RayCare for installation at CRO National Cancer Institute (C.R.O.)
  • RaySearch has received an order from Israel-based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

Implantica's RefluxStop™ health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world's leading European Health-Economics Conference

Retrieved on: 
Thursday, November 16, 2023
International Society, Research, Pharmacoeconomics, GERD, Patient, CET, University of York, HTA, Certification, Abstract, ISPOR, Systematic review, Health technology assessment, Medical device, Payment

The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.

Key Points: 
  • The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.
  • The Quality-of-Life analysis of GERD patients clearly showed that surgical management of GERD leads to a better Quality-of-Life than disease management through medication.
  • ISPOR is globally recognized as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in the healthcare decision-making process.
  • To present such impactful economic data and be selected in the "Top 5% poster category" at ISPOR is a true honor for Implantica.

Implantica's RefluxStop™ makes an impact at the leading Annual European Foregut Society Meeting

Retrieved on: 
Wednesday, November 15, 2023
Associate, EFS, GERD, Surgeon, Teaching hospital, Patient, CET, ARB, Scientific programming language, Humble, Texas, GI, Certification, Congress, Quality of life, Deutsche Medizinische Wochenschrift, Health

), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.
  • The Scientific Program at EFS included the symposium, 'Reconstruction of the Anti-Reflux Barrier (ARB) with RefluxStop™- an innovative approach.'
  • This well-attended event, filled with lively conversation, offered an opportunity to learn directly from experts with real-world experience performing the RefluxStop™ procedure.
  • Dr. Forsell goes on to say, "The 3rd Annual EFS Meeting gave Implantica the opportunity to spotlight RefluxStop™ and report on the excellent clinical data.

Nagarro posts 12.9% YoY constant-currency revenue growth in 9M 2023

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Q3, EBIT, GMT, IST, CET, GST, Net, SGT, Organic, Growth, Beauty salon, Flour, Entrepreneurship

In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.

Key Points: 
  • In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.
  • Adjusted EBITDA declined to €32.0 million (13.7% of revenue) in Q3 2023 from €48.4 million (21.1% of revenue) in Q3 2022.
  • Revenue grew to €690.6 million in 9M 2023, up 10.4% YoY from €625.4 million in 9M 2022.
  • Adjusted EBITDA declined to €92.4 million (13.4% of revenue) in 9M 2023 from €117.6 million (18.8% of revenue) in 9M 2022.

Nagarro posts 12.9% YoY constant-currency revenue growth in 9M 2023

Retrieved on: 
Tuesday, November 14, 2023
EBITDA, Q3, EBIT, GMT, IST, CET, GST, Net, SGT, Organic, Growth, Beauty salon, Flour, Entrepreneurship

In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.

Key Points: 
  • In Q3 2023, revenue grew to €234.3 million, up 1.9% YoY from €229.8 million in Q3 2022 and up 6.6% YoY in constant currency.
  • Adjusted EBITDA declined to €32.0 million (13.7% of revenue) in Q3 2023 from €48.4 million (21.1% of revenue) in Q3 2022.
  • Revenue grew to €690.6 million in 9M 2023, up 10.4% YoY from €625.4 million in 9M 2022.
  • Adjusted EBITDA declined to €92.4 million (13.4% of revenue) in 9M 2023 from €117.6 million (18.8% of revenue) in 9M 2022.

Implantica takes a big step forward at its 2nd Annual RefluxStop™ Users Meeting

Retrieved on: 
Tuesday, November 14, 2023
EFS, Surgeon, Learning, History, Patient, CET, AFS, Certification, Gastroesophageal reflux disease, Nursing, Dentistry, Pharmaceutical industry, GERD

Implantica conducted its second global users meeting discussing clinical and commercial advancements of RefluxStop™ therapy involving more than 50 attendees including current and also upcoming RefluxStop™ surgeons as well as gastrointestinal physicians from across Europe, UK, US, and Canada.

Key Points: 
  • Implantica conducted its second global users meeting discussing clinical and commercial advancements of RefluxStop™ therapy involving more than 50 attendees including current and also upcoming RefluxStop™ surgeons as well as gastrointestinal physicians from across Europe, UK, US, and Canada.
  • Current, past and upcoming Presidents of the medical societies EFS (European Foregut Society) and AFS (American Foregut Society) were in attendance, including several Board members.
  • "It's rewarding to see the growing numbers of key surgeons around the world offering or interested in offering the RefluxStop™ therapy to patients.
  • The participants in the meeting really experienced the excitement around the impact of the RefluxStop procedure.

Sweco presents its growth strategy at the Capital Markets Day

Retrieved on: 
Tuesday, November 14, 2023
Capital market, CET, Engineering, Central business district, CFO, Architecture, Management, Broadcasting, Sweco

STOCKHOLM, Nov. 14, 2023 /PRNewswire/ -- At the Capital Markets Day, Sweco (NASDAQ: SWEC-B) reiterates its financial targets and presents the company's strategy to strengthen its position as the leading engineering and architecture consultancy in Europe.

Key Points: 
  • STOCKHOLM, Nov. 14, 2023 /PRNewswire/ -- At the Capital Markets Day, Sweco (NASDAQ: SWEC-B) reiterates its financial targets and presents the company's strategy to strengthen its position as the leading engineering and architecture consultancy in Europe.
  • Sweco is already a leading advisor in the green transition in Europe and we are well-positioned to continue capturing long-term growth opportunities.
  • Our strategy of combining organic growth with strategic acquisitions will remain crucial and we have made 10 acquisitions so far this year, with a total turnover of close to 2 billion SEK", says Åsa Bergman, President and CEO of Sweco.
  • Key topics at the webcasted Capital Markets Day include:
    During the Capital Markets Day, Sweco reiterates its financial targets:
    More information at webcast today, November 14th, at 08:30 CET
    Sweco's Capital Markets Day will be conducted in English and will be web casted live online here from 08:30 CET and conclude at around 12:00.

EQS-News: Brockhaus Technologies AG: Brockhaus Technologies continues dynamic and highly profitable growth in the first nine months; full year 2023 expected at the upper end of the forecast

Retrieved on: 
Thursday, December 14, 2023
Growth, Optimism, Financial Technologies Group, CET, EBIT, Core Security Technologies, Interest, EBITDA, Acquisition, ISIN, Bridge, Security (finance), Bookkeeping, Marketing, Clothing, Fine chemical, Video game, D2C

Brockhaus Technologies AG: Brockhaus Technologies continues dynamic and highly profitable growth in the first nine months; full year 2023 expected at the upper end of the forecast

Key Points: 
  • Brockhaus Technologies AG: Brockhaus Technologies continues dynamic and highly profitable growth in the first nine months; full year 2023 expected at the upper end of the forecast
    The issuer is solely responsible for the content of this announcement.
  • Adjusted EBIT increased by +33% to €51.2 million and the corresponding margin to 35.9% (9M 2022: €38.6 million; 35.4% margin).
  • "We continue to deliver what we promised also for 2023: dynamic and highly profitable growth.
  • BKHT will be able to drive further organic and inorganic growth on the back of its very healthy balance sheet.

EQS-News: Elmos targets 40% reduction in greenhouse gas emissions for its own activities by 2026 and climate neutrality by 2035

Retrieved on: 
Thursday, December 14, 2023
CET, ESG, Climate change, Elmos Semiconductor, Sale, Littelfuse, GHG, Renewable energy

Dortmund, November 13, 2023: Elmos Semiconductor SE has set ambitious climate targets in its sustainability strategy with the aim of actively reducing greenhouse gas emissions and mitigating climate change.

Key Points: 
  • Dortmund, November 13, 2023: Elmos Semiconductor SE has set ambitious climate targets in its sustainability strategy with the aim of actively reducing greenhouse gas emissions and mitigating climate change.
  • In a first step, Elmos plans to cut greenhouse gas (GHG) emissions for its own activities, i.e., Scope 1 and 2 emissions, by 40% until 2026 compared to the base year 2022.
  • In order to achieve this significant reduction, GHG emissions are to be cut by 10% annually over the next four years.
  • Our ambitious climate targets represent another step towards improved climate action and a more livable future,” says Dr. Arne Schneider, CEO of Elmos Semiconductor SE.